The International Working Group recommends that Alzheimer’s disease is a clinical–biological entity defined by a specific clinical phenotype associated with in vivo Aβ and tau biomarkers; thus, Alzheimer’s disease should be diagnosed for individuals with both positive biomarkers and specific clinical manifestations of Alzheimer’s disease. Here, MAPT is linked to Alzheimer disease.